SOLIGENIX, INC.
SOLIGENIX, INC. (SNGX): 7 pipeline candidates · 2 upcoming catalysts · ~8 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
7.9 months
D/E 1.24 · 0% dilution
Lead: Phase 3
7 candidates
2 upcoming, next in ~105d
N/A
A transparent, data-derived signal for SOLIGENIX, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.4M
Cash
$6.0M
Quarterly Burn
$2.4M
Runway
7.9 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| civax | Preclinical |
| dusquetide | Phase 2 |
| hybryte | Phase 3 |
| hypericin | Phase 2 |
| mechlorethamine | Phase 2 |
| sgx302 | Phase 3 |
| sgx943 | Preclinical |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$373K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 120,267 | $142K |
| vanguard capital management llc | 116,800 | $138K |
| vanguard fiduciary trust co | 53,914 | $64K |
| xtx topco ltd | 20,799 | $25K |
| morgan stanley | 3,592 | $4K |
| plante moran financial advisors, llc | 209 | $247 |
| jones financial companies lllp | 100 | $113 |
| citigroup inc | 19 | $22 |
| cwm, llc | 6 | $7 |
| albion financial group /ut | 1 | $2 |
Showing top 10 of 11 institutional holders of SOLIGENIX, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SOLIGENIX, INC.'s pipeline?
SOLIGENIX, INC. (SNGX) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SOLIGENIX, INC.'s lead drug candidate?
SOLIGENIX, INC.'s most advanced tracked candidate is civax (Preclinical) for Prevention of COVID-19.
What is SOLIGENIX, INC.'s next catalyst?
SOLIGENIX, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effica" — expected October 1, 2026.
What is SOLIGENIX, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SOLIGENIX, INC. has approximately 7.9 months of cash runway.
What is SOLIGENIX, INC.'s market capitalization?
SOLIGENIX, INC.'s market capitalization is approximately $6.4M.
Get the full picture on SOLIGENIX, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.